Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 226

1.

Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis.

Falck RS, Wang J, Carlson RG.

J Psychopharmacol. 2008 Jan;22(1):47-54. doi: 10.1177/0269881107078293.

PMID:
18187532
[PubMed - indexed for MEDLINE]
2.

Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio.

Falck RS, Wang J, Carlson RG, Siegal HA.

Addict Behav. 2006 Jan;31(1):90-101.

PMID:
15922511
[PubMed - indexed for MEDLINE]
3.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
[PubMed - indexed for MEDLINE]
4.

Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.

Soar K, Turner JJ, Parrott AC.

J Psychopharmacol. 2006 May;20(3):417-24.

PMID:
16574716
[PubMed - indexed for MEDLINE]
5.

Altered response to tryptophan supplementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function.

Curran HV, Verheyden SL.

Psychopharmacology (Berl). 2003 Aug;169(1):91-103. Epub 2003 May 21.

PMID:
12759801
[PubMed - indexed for MEDLINE]
6.

Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

de Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W.

Psychopharmacology (Berl). 2004 May;173(3-4):376-82. Epub 2004 Jan 15.

PMID:
14726997
[PubMed - indexed for MEDLINE]
7.

Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms.

MacInnes N, Handley SL, Harding GF.

J Psychopharmacol. 2001 Sep;15(3):181-6.

PMID:
11565625
[PubMed - indexed for MEDLINE]
8.

Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.

Verheyden SL, Maidment R, Curran HV.

J Psychopharmacol. 2003 Dec;17(4):371-8.

PMID:
14870948
[PubMed - indexed for MEDLINE]
9.

Recreational ecstasy use and depression.

Guillot C, Greenway D.

J Psychopharmacol. 2006 May;20(3):411-6.

PMID:
16574715
[PubMed - indexed for MEDLINE]
10.

Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study.

Murphy PN, Wareing M, Fisk J.

J Psychopharmacol. 2006 May;20(3):447-55.

PMID:
16574719
[PubMed - indexed for MEDLINE]
11.

Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences.

Verheyden SL, Hadfield J, Calin T, Curran HV.

Psychopharmacology (Berl). 2002 Apr;161(1):23-31. Epub 2002 Mar 6.

PMID:
11967627
[PubMed - indexed for MEDLINE]
12.

Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.

Parrott AC, Milani RM, Parmar R, Turner JD.

Psychopharmacology (Berl). 2001 Dec;159(1):77-82. Epub 2001 Sep 11.

PMID:
11797073
[PubMed - indexed for MEDLINE]
13.

[A case of acute psychotic episode after a single dose of ecstasy].

Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M.

Encephale. 2001 Mar-Apr;27(2):198-202. French.

PMID:
11407274
[PubMed - indexed for MEDLINE]
14.

Brain serotonin transporter binding in former users of MDMA ('ecstasy').

Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P, Curran HV, Grasby P.

Br J Psychiatry. 2009 Apr;194(4):355-9. doi: 10.1192/bjp.bp.108.050344.

PMID:
19336788
[PubMed - indexed for MEDLINE]
Free Article
15.

Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.

Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E.

Psychopharmacology (Berl). 2004 May;173(3-4):398-404. Epub 2004 Jan 14.

PMID:
14722704
[PubMed - indexed for MEDLINE]
16.

Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.

Verheyden SL, Henry JA, Curran HV.

Hum Psychopharmacol. 2003 Oct;18(7):507-17.

PMID:
14533132
[PubMed - indexed for MEDLINE]
17.

Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.

Parrott AC, Sisk E, Turner JJ.

Drug Alcohol Depend. 2000 Jul 1;60(1):105-10.

PMID:
10821995
[PubMed - indexed for MEDLINE]
18.

Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.

Bedi G, Van Dam NT, Redman J.

J Psychopharmacol. 2010 Feb;24(2):233-40. doi: 10.1177/0269881108097631. Epub 2008 Oct 2.

PMID:
18832429
[PubMed - indexed for MEDLINE]
19.

Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users.

Milani RM, Parrott AC, Turner JJ, Fox HC.

Addict Behav. 2004 Jul;29(5):965-71.

PMID:
15219343
[PubMed - indexed for MEDLINE]
20.

Mental disorders in current and former heavy ecstasy (MDMA) users.

Thomasius R, Petersen KU, Zapletalova P, Wartberg L, Zeichner D, Schmoldt A.

Addiction. 2005 Sep;100(9):1310-9.

PMID:
16128720
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk